5Rowhrborm CG, McConnell JD. Etiology, pathothysiology, epidemiology and natural history of binign prostatic hyperplasia// Campbell' s Urology. Philadelphia: Saunders Company, 2002 : 1297-1330.
6Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: the health professionals follow up study. J Urol, 1999, 162:376-382.
7Rule AD, Laeber MM, Jacobsen SJ, et al. Is benign prostatic hyperplasia a risk factor for chronic renal failure? J Urol, 2005, 173:691-696.
8McConnell JD, Roehrborn CG, Baustita OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003, 349:2387-2398.
9Jacobsen SJ, Jacobson DJ, Girman C J, et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol, 1999, 162:1301-1306.
10Roehrbohn CG, McConnell JD, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia: PLESS study. J Urol, 2000, 163:13-20.
